This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Somerville, K. T. Search for Related Content Social Bookmarking                   What's this?

Antibody Agents in Solid Organ Transplantation

University of Utah Health Sciences Center, College of Pharmacy, Salt Lake City, Utahtroy.somerville{at}hfc.utah.edu

Antibody agents play an important role in the pharmacotherapy of solid organ transplantation. These agents can be either monoclonal or polyclonal, derived from an animal source or genetically engineered utilizing human antibody sequences. This reviewpresents basic pharmacology and therapeutic issues related to the antibody preparations utilized in transplantation including equine and rabbit antithymocyte globulins, muromonab-CD3, daclizumab, and basiliximab. The parameters covered for these agents include mechanism of action, pharmacokinetics, pharmacodynamic monitoring strategies, clinical dosing, adverse effects, and clinical trials. The brief overviewof current clinical data related to these agents focuses on kidney transplantation. The use of these very powerful agents in different patient populations needs to be individualized based on certain risks and these data are presented to help in the decision-making process, especially for renal allograft recipients.

Key Words: Antibody immunosuppressive agents • transplantation • induction immunosuppression

Journal of Pharmacy Practice, Vol. 16, No. 6, 388-400 (2003)
DOI: 10.1177/0897190003259835


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?